Cargando…
Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis
BACKGROUND: Mucositis is one of the most relevant gastrointestinal inflammatory conditions in humans, generated by the use of chemotherapy drugs, such as 5-fluoracil (5-FU). 5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great dis...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307810/ https://www.ncbi.nlm.nih.gov/pubmed/28193209 http://dx.doi.org/10.1186/s12934-017-0624-x |
_version_ | 1782507436953829376 |
---|---|
author | Carvalho, Rodrigo D. Breyner, Natalia Menezes-Garcia, Zelia Rodrigues, Nubia M. Lemos, Luisa Maioli, Tatiane U. da Gloria Souza, Danielle Carmona, Denise de Faria, Ana M. C. Langella, Philippe Chatel, Jean-Marc Bermúdez-Humarán, Luis G. Figueiredo, Henrique C. P. Azevedo, Vasco de Azevedo, Marcela S. |
author_facet | Carvalho, Rodrigo D. Breyner, Natalia Menezes-Garcia, Zelia Rodrigues, Nubia M. Lemos, Luisa Maioli, Tatiane U. da Gloria Souza, Danielle Carmona, Denise de Faria, Ana M. C. Langella, Philippe Chatel, Jean-Marc Bermúdez-Humarán, Luis G. Figueiredo, Henrique C. P. Azevedo, Vasco de Azevedo, Marcela S. |
author_sort | Carvalho, Rodrigo D. |
collection | PubMed |
description | BACKGROUND: Mucositis is one of the most relevant gastrointestinal inflammatory conditions in humans, generated by the use of chemotherapy drugs, such as 5-fluoracil (5-FU). 5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great discomfort. As current therapy drugs presents limitations in alleviating mucositis symptoms, alternative strategies are being pursued. Recent studies have shown that the antimicrobial pancreatitis-associated protein (PAP) has a protective role in intestinal inflammatory processes. Indeed, it was demonstrated that a recombinant strain of Lactococcus lactis expressing human PAP (LL-PAP) could prevent and improve murine DNBS-induced colitis, an inflammatory bowel disease (IBD) that causes severe inflammation of the colon. Hence, in this study we sought to evaluate the protective effects of LL-PAP on 5-FU-induced experimental mucositis in BALB/c mice as a novel approach to treat the disease. RESULTS: Our results show that non-recombinant L. lactis NZ9000 have antagonistic activity, in vitro, against the enteroinvasive gastrointestinal pathogen L. monocytogenes and confirmed PAP inhibitory effect against Opportunistic E. faecalis. Moreover, L. lactis was able to prevent histological damage, reduce neutrophil and eosinophil infiltration and secretory Immunoglobulin-A in mice injected with 5-FU. Recombinant lactococci carrying antimicrobial PAP did not improve those markers of inflammation, although its expression was associated with villous architecture preservation and increased secretory granules density inside Paneth cells in response to 5-FU inflammation. CONCLUSIONS: We have demonstrated for the first time that L. lactis NZ9000 by itself, is able to prevent 5-FU-induced intestinal inflammation in BALB/c mice. Moreover, PAP delivered by recombinant L. lactis strain showed additional protective effects in mice epithelium, revealing to be a promising strategy to treat intestinal mucositis. |
format | Online Article Text |
id | pubmed-5307810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53078102017-02-22 Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis Carvalho, Rodrigo D. Breyner, Natalia Menezes-Garcia, Zelia Rodrigues, Nubia M. Lemos, Luisa Maioli, Tatiane U. da Gloria Souza, Danielle Carmona, Denise de Faria, Ana M. C. Langella, Philippe Chatel, Jean-Marc Bermúdez-Humarán, Luis G. Figueiredo, Henrique C. P. Azevedo, Vasco de Azevedo, Marcela S. Microb Cell Fact Research BACKGROUND: Mucositis is one of the most relevant gastrointestinal inflammatory conditions in humans, generated by the use of chemotherapy drugs, such as 5-fluoracil (5-FU). 5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great discomfort. As current therapy drugs presents limitations in alleviating mucositis symptoms, alternative strategies are being pursued. Recent studies have shown that the antimicrobial pancreatitis-associated protein (PAP) has a protective role in intestinal inflammatory processes. Indeed, it was demonstrated that a recombinant strain of Lactococcus lactis expressing human PAP (LL-PAP) could prevent and improve murine DNBS-induced colitis, an inflammatory bowel disease (IBD) that causes severe inflammation of the colon. Hence, in this study we sought to evaluate the protective effects of LL-PAP on 5-FU-induced experimental mucositis in BALB/c mice as a novel approach to treat the disease. RESULTS: Our results show that non-recombinant L. lactis NZ9000 have antagonistic activity, in vitro, against the enteroinvasive gastrointestinal pathogen L. monocytogenes and confirmed PAP inhibitory effect against Opportunistic E. faecalis. Moreover, L. lactis was able to prevent histological damage, reduce neutrophil and eosinophil infiltration and secretory Immunoglobulin-A in mice injected with 5-FU. Recombinant lactococci carrying antimicrobial PAP did not improve those markers of inflammation, although its expression was associated with villous architecture preservation and increased secretory granules density inside Paneth cells in response to 5-FU inflammation. CONCLUSIONS: We have demonstrated for the first time that L. lactis NZ9000 by itself, is able to prevent 5-FU-induced intestinal inflammation in BALB/c mice. Moreover, PAP delivered by recombinant L. lactis strain showed additional protective effects in mice epithelium, revealing to be a promising strategy to treat intestinal mucositis. BioMed Central 2017-02-13 /pmc/articles/PMC5307810/ /pubmed/28193209 http://dx.doi.org/10.1186/s12934-017-0624-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Carvalho, Rodrigo D. Breyner, Natalia Menezes-Garcia, Zelia Rodrigues, Nubia M. Lemos, Luisa Maioli, Tatiane U. da Gloria Souza, Danielle Carmona, Denise de Faria, Ana M. C. Langella, Philippe Chatel, Jean-Marc Bermúdez-Humarán, Luis G. Figueiredo, Henrique C. P. Azevedo, Vasco de Azevedo, Marcela S. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title_full | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title_fullStr | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title_full_unstemmed | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title_short | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis |
title_sort | secretion of biologically active pancreatitis-associated protein i (pap) by genetically modified dairy lactococcus lactis nz9000 in the prevention of intestinal mucositis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307810/ https://www.ncbi.nlm.nih.gov/pubmed/28193209 http://dx.doi.org/10.1186/s12934-017-0624-x |
work_keys_str_mv | AT carvalhorodrigod secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT breynernatalia secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT menezesgarciazelia secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT rodriguesnubiam secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT lemosluisa secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT maiolitatianeu secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT dagloriasouzadanielle secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT carmonadenise secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT defariaanamc secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT langellaphilippe secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT chateljeanmarc secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT bermudezhumaranluisg secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT figueiredohenriquecp secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT azevedovasco secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis AT deazevedomarcelas secretionofbiologicallyactivepancreatitisassociatedproteinipapbygeneticallymodifieddairylactococcuslactisnz9000inthepreventionofintestinalmucositis |